Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide
نویسندگان
چکیده
منابع مشابه
Plerixafor use for peripheral blood stem cell mobilization in Korea
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Hematologic Malignancy Branch, National Cancer Center, Ilsan, Department of Internal Medicine, St. Mary Hospital, The Catholic University of Korea...
متن کاملPlerixafor for autologous CD34+ cell mobilization
High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34(+) cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis b...
متن کاملAdvances in Hematopoietic Stem Cell Mobilization and Peripheral Blood Stem Cell Transplantation
Hematopoietic stem/progenitor cells (HSPCs) which give rise to different blood cell types are present within the bone marrow microenvironment, especially in flat bones such as skull, vertebrae, pelvis and chest. Interacting factors such as stromal derived factor-1/CXCR4, very late antigen-4/vascular cell adhesion molecule-1, Lymphocyte function-associated antigen-1/ intercellular adhesion molec...
متن کاملPlerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.
BACKGROUND High-dose chemotherapy with autologous stem-cell transplantation (asct) is an accepted part of standard therapy for patients with hematologic malignancies. Usually, stem-cell mobilization uses granulocyte colony-stimulating factor (g-csf); however, some patients are not able to be mobilized with chemotherapy and g-csf, and such patients could be at higher risk of failing mobilization...
متن کاملLong-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients
Poor peripheral blood stem cell (PBSC) mobilization predicts worse outcome for myeloma and lymphoma patients post autologous stem cell transplant (ASCT). We hypothesize that PBSC harvest using plerixafor and G-CSF in poor mobilizers may improve long-term outcome. We retrospectively analyzed the data on patients who had second PBSC mobilization using plerixafor and G-CSF as a rescue. Nine lympho...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2011
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v118.21.1932.1932